Skip to main content
Premium Trial:

Request an Annual Quote

Metabolon, MGH Partner on Biomarker Discovery for Type I Diabetes

NEW YORK, March 29 (GenomeWeb News) - Metabolon and Massachusetts General Hospital hope to co-discover biomarkers for diabetic nephropathy in type I diabetes, Metabolon said today.

 

The study has been funded by a two-year grant awarded to MGH's Darryl Palmer-Toy by the National Institute of Diabetes and Digestive and Kidney Diseases. The amount of funding for fiscal year 2004, which began on Oct.  1, is worth $365,000.

 

Metabolon will test patient urine and plasma samples with its metabolomics platform to search for signatures that predict the likelihood of developing diabetic nephropathy, Metabolon said.

 

This is the second collaboration announced between Metabolon and MGH in the past year. In August, Metabolon and MGH announced a collaborative biomarker study for amyotrophic lateral sclerosis.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.